Drug Development - Publications - Faculty & Research

Richard M. Furlaud

Furlaud focused on Squibb's pharmaceuticals, investing in research and development that ultimately led to the introduction of several new drugs. Furlaud's streamlining and consistent support of the company's cardiovascular View Details

Keywords: Healthcare

01 Jan 2002
News

Raymond V. Gilmartin (MBA '68)

The blind man depicted in the sculpture suffers from river blindness, a disease that ravaged countless lives in the developing world until Merck researchers discovered the breakthrough drug Mectizan. The... View Details

Student-Profile

Olivia Zhao

pros and cons of a public system facing increased privatization. Research Olivia’s research hones in on the pharmaceutical industry and looking at the lifecycle of a drug. “It starts, of course, with research and development at huge View Details

08 Mar 2016
First Look

March 8, 2016

cultural model and undermine their own positions with inappropriate use of symbolic market-creation actions. Download working paper: https://www.hbs.edu/faculty/Pages/item.aspx?num=50701 Harvard Business School Case 916-026 Express Scripts: Promoting Prescription View Details

Keywords: Sean Silverthorne

24 Apr 2014
News

Finding a cure so that others may benefit

call. The foundation wanted to invest in for-profit bioscience companies to spur scientists to find a cure for the disease. O’Donnell is credited with almost singlehandedly raising $250 million in support of this venture philanthropy, which led to the View Details

Web

Neil Band | MBA

track in tech entrepreneurship. Tech areas of interest: I’m fascinated by the application of machine learning, distributed systems, and cryptography to economics and biology. I currently research memory optimization in deep neural network training, and reinforcement... View Details

01 Mar 2010
News

Noted & Quoted

“Unfortunately, the technology for growing flu viruses to make vaccines is fifty years old — it’s chicken eggs.” — HBS Professor of Management Practice and former Merck CEO Raymond Gilmartin, at a November HBS panel discussion on drug... View Details

Keywords: Educational Services; Information

19 Sep 2012
Research & Ideas

Funding Innovation: Is Your Firm Doing it Wrong?

programs to an investment board comprising both insiders (senior GSK executives) and outsiders (including a venture capitalist and a biotech CEO). After a three-month review period, successful teams are awarded three years worth of investment funding. Because View Details

Keywords: by Carmen Nobel

19 Sep 2017
First Look

First Look at New Research and Ideas, September 19

this case: https://cb.hbsp.harvard.edu/cbmp/product/717497-PDF-ENG Harvard Business School Case 717-498 Imprimis (D) This case is a supplement to Imprimis (A, B, & C). It describes Imprimis’s 2015 decision to develop a $1 per pill... View Details

Keywords: Sean Silverthorne

20 Dec 2018
Research & Ideas

Most Popular Stories and Research Papers of 2018

Cirrus Foroughi, and Barbara Larson. Developing Novel Drugs This paper by Joshua Krieger and colleagues contributes to our understanding of how financing constraints affect the direction of innovation in... View Details

Keywords: by Sean Silverthorne

02 Feb 2021
Blog Post

Finding My Focus in Health care Amidst a Global Pandemic

presidential election as it unfolded in real-time, which was a highlight. In addition, we engaged with Dr. Amy Abernethy, Deputy Principal Commissioner of the FDA, and John Young, Chief Business Officer of Pfizer, to discuss the future of View Details

10 Sep 2008
Research & Ideas

Long-Tail Economics? Give Me Blockbusters!

by focusing on bigger films that require a bigger commitment." Jeff Robinov believes in blockbusters and his strategy is to create more of them. The pharmaceutical and entertainment industries are similar. R&D costs in both are high. Results are unpredictable.... View Details

Keywords: by John Quelch; Entertainment & Recreation; Pharmaceutical

01 Jun 2016
News

@Soldiers Field

diverse, outstanding future leaders and who will go on to make a real difference in the world.” Baker Library’s Historical Collections acquired a trove of archival materials from Genzyme, one of the world’s leading biotechnology firms. A pioneer in the View Details

01 Jan 2003
News

Daniel L. Vasella, M.D.

quickly," he observes. Under his guidance, Novartis has been a leader not only in developing new drugs but in making them accessible to those in need around the globe. Dan Vasella has experienced first-hand... View Details

17 Jun 2019
Blog Post

Why I Would Have Applied to the MS/MBA Biotechnology: Life Sciences Program

and drug development. These qualities straddle the science and business fields – for example, to instill a science-focused culture within an organization, or to craft a drug View Details

25 Aug 2014
News

Wendell P. Weeks, MBA 1987

brink of failure through a painful restructuring and commitment to both innovation and the diversification of its product lines. “We make products that change the world,” he says, noting Corning’s development of LCD glass; tools to... View Details

Keywords: Susan Young

Profile

Arjun Goyal

a scientific eye for identifying precise populations in which therapies are effective, with a commercial appetite for successful drugs that need more time and money to prove their potential.” As part of a four-person clinical View Details

05 May 2020
News

“Walking a Tightrope”

Kristof, most of which have focused on poverty in developing countries. But in the Pulitzer Prize-winning duo’s latest book, Tightrope: Americans Reaching for Hope, they turn their lens on working class communities in the United... View Details

01 Jun 2018
News

The Long Run

trajectory of overdose deaths from prescription drugs and heroin. According to the Centers for Disease Control and Prevention, the US death rate from opioid overdose has increased over 400 percent since 1999; the picture is even grimmer... View Details

Keywords: Julia Hanna; photographed by Melissa Golden

07 Apr 2003
Research & Ideas

Three Steps for Crisis Prevention

companies feared that the precedent set by the South African move would undermine their control over valuable intellectual property in the developing world. But the suit sparked international outrage against the industry, prompting a very... View Details

Keywords: by Michael D. Watkins & Max H. Bazerman

Publications